Stella Pharma Corporation (4888.T)
JPY 555.0
(0.18%)
JPY 555.0
(0.18%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 963.98 Million JPY | -3.56% |
| 2022 | 1.01 Billion JPY | 22.61% |
| 2021 | 826.76 Million JPY | -4.13% |
| 2020 | 862.34 Million JPY | -10.17% |
| 2019 | 960 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 209.93 Million JPY | -39.67% |
| 2023 Q2 | 206.93 Million JPY | -4.8% |
| 2023 FY | 977.59 Million JPY | -3.56% |
| 2023 Q4 | 347.94 Million JPY | 69.45% |
| 2023 Q3 | 205.34 Million JPY | -0.77% |
| 2023 Q1 | 217.36 Million JPY | -38.14% |
| 2022 Q3 | 200.82 Million JPY | -3.21% |
| 2022 FY | 1.01 Billion JPY | 22.61% |
| 2022 Q4 | 351.37 Million JPY | 74.97% |
| 2022 Q2 | 207.48 Million JPY | 0.0% |
| 2021 FY | 826.76 Million JPY | -4.13% |
| 2020 FY | 862.34 Million JPY | -10.17% |
| 2019 FY | 960 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | 24.951% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -67.122% |
| GNI Group Ltd. | 9.32 Billion JPY | 89.659% |
| Linical Co., Ltd. | 2.7 Billion JPY | 64.365% |
| Trans Genic Inc. | 2.15 Billion JPY | 55.367% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 35.353% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 68.611% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 48.088% |
| AnGes, Inc. | 8.9 Billion JPY | 89.171% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -2.217% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 94.977% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -133.416% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | 1.167% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 62.455% |
| CanBas Co., Ltd. | 278 Million JPY | -246.757% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | 15.554% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 46.974% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 39.892% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 59.395% |
| PeptiDream Inc. | 9.68 Billion JPY | 90.049% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 50.832% |
| Ribomic Inc. | 1.1 Billion JPY | 12.816% |
| SanBio Company Limited | 4.53 Billion JPY | 78.762% |
| Healios K.K. | 3.48 Billion JPY | 72.355% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | 16.519% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 27.762% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 31.314% |
| StemRIM | 2.07 Billion JPY | 53.565% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 50.905% |
| FunPep Company Limited | 313.82 Million JPY | -207.177% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -0.623% |
| TMS Co., Ltd. | 943.25 Million JPY | -2.198% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | 11.557% |
| Cuorips Inc. | 598.11 Million JPY | -61.17% |
| K Pharma,Inc. | 543.94 Million JPY | -77.222% |
| Takara Bio Inc. | 23.9 Billion JPY | 95.967% |
| ReproCELL Incorporated | 1.51 Billion JPY | 36.329% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | 18.582% |
| StemCell Institute Inc. | 1.16 Billion JPY | 17.05% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 36.675% |
| CellSeed Inc. | 804.93 Million JPY | -19.76% |